科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background Heparin therapy is difficult to monitor due to variation in animal response. While laboratory measurements of activated partial thromboplasin time (aPTT) and Anti-Xa activity (AXA) accurately describe heparin effect, their availability is limited. Hypothesis Sonoclot analysis would be as sensitive as AXA and aPTT to monitor effects of unfractionated heparin (UFH) in healthy adult dogs. Animals Six adult mixed-breed dogs. Methods A prospective study design was employed. On day 1, baseline samples were collected (CBC, PT, aPTT, and Sonoclot), and UFH (300 similar to U/kg SC) was administered to 6 dogs following an IV loading dose of 50 similar to U/kg. Sonoclot and aPTT were performed hourly for 12 similar to hours. AXA was assayed at hours 3, 6, 9, and 12. UFH (300 similar to U/kg similar to q8 similar to h SC) was administered at 12 similar to hours, and subsequently (q8 similar to h) for 2 additional days. On day 4, a final dose of UFH was administered, and a sampling protocol identical to day 1 was performed. Results Sonoclot activated clotting time (ACT) and clot rate (CR) correlated with AXA (R similar to 0.69, R similar to 0.65, respectively, P similar to 001), although to a lesser degree than aPTT (R similar to 0.75, P similar to 001). Linear regression using ACT and CR as covariates indicated a stronger correlation with AXA (R similar to 0.73, P similar to 001). ACT values strongly correlated with aPTT (R similar to 0.87, P similar to 001). Conclusions and Clinical Importance Administration of UFH to healthy dogs results in progressive changes in Sonoclot values. AXA was correlated with a combination of ACT and CR and with aPTT. Sonoclot may play a role in monitoring UFH therapy; however, prospective studies evaluating its utility in clinical cases are warranted.
- 出版日期2012-6
